583 related articles for article (PubMed ID: 24367715)
1. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
2. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.
Falzarano D; Feldmann F; Grolla A; Leung A; Ebihara H; Strong JE; Marzi A; Takada A; Jones S; Gren J; Geisbert J; Jones SM; Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1082-9. PubMed ID: 21987745
[TBL] [Abstract][Full Text] [Related]
3. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
5. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
[TBL] [Abstract][Full Text] [Related]
6. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
[TBL] [Abstract][Full Text] [Related]
7. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
Hensley LE; Mulangu S; Asiedu C; Johnson J; Honko AN; Stanley D; Fabozzi G; Nichol ST; Ksiazek TG; Rollin PE; Wahl-Jensen V; Bailey M; Jahrling PB; Roederer M; Koup RA; Sullivan NJ
PLoS Pathog; 2010 May; 6(5):e1000904. PubMed ID: 20502688
[TBL] [Abstract][Full Text] [Related]
9. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
Front Immunol; 2021; 12():703986. PubMed ID: 34484200
[TBL] [Abstract][Full Text] [Related]
11. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
12. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1075-81. PubMed ID: 21987744
[TBL] [Abstract][Full Text] [Related]
13. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
[TBL] [Abstract][Full Text] [Related]
14. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
Mire CE; Miller AD; Carville A; Westmoreland SV; Geisbert JB; Mansfield KG; Feldmann H; Hensley LE; Geisbert TW
PLoS Negl Trop Dis; 2012; 6(3):e1567. PubMed ID: 22448291
[TBL] [Abstract][Full Text] [Related]
15. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
16. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.
Geisbert TW; Daddario-DiCaprio KM; Williams KJ; Geisbert JB; Leung A; Feldmann F; Hensley LE; Feldmann H; Jones SM
J Virol; 2008 Jun; 82(11):5664-8. PubMed ID: 18385248
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
mBio; 2019 May; 10(3):. PubMed ID: 31138743
[TBL] [Abstract][Full Text] [Related]
18. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
Geisbert TW; Daddario-Dicaprio KM; Geisbert JB; Reed DS; Feldmann F; Grolla A; Ströher U; Fritz EA; Hensley LE; Jones SM; Feldmann H
Vaccine; 2008 Dec; 26(52):6894-900. PubMed ID: 18930776
[TBL] [Abstract][Full Text] [Related]
19. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
